Baxter Intends To Use After-Tax Proceeds From Kidney Care Transaction To Reduce Its Debt, Consistent With Its Stated Capital Allocation Priorities
Portfolio Pulse from Benzinga Newsdesk
Baxter International plans to use after-tax proceeds from its upcoming kidney care transaction to reduce its debt, aligning with its capital allocation priorities. The transaction is expected to close in late 2024 or early 2025, pending regulatory approvals and other conditions.
August 13, 2024 | 11:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baxter International plans to use proceeds from its kidney care transaction to reduce its debt, which aligns with its capital allocation priorities. The transaction is expected to close in late 2024 or early 2025, subject to regulatory approvals.
The planned use of proceeds to reduce debt is a positive move for Baxter International, as it aligns with their capital allocation priorities and can improve their financial health. The transaction's expected closure by early 2025, pending regulatory approvals, adds a timeline for investors to watch.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100